TFF, U.S. Army achieve milestone in freeze-dried biodefense therapies

By The Science Advisory Board staff writers

February 19, 2021 -- TFF Pharmaceuticals, in collaboration with the U.S. Army Medical Research Institute of Infectious Diseases (USAMRID), has announced positive preclinical in vitro efficacy data from TFF-formulated biodefense countermeasures utilizing its thin-film freeze-drying (TFFD) technology platform.

In April 2020, the company entered into a three-year cooperative research and development agreement with the USAMRID to investigate TFFD of various biodefense countermeasures against biological warfare to demonstrate the use of needle-free, inhaled treatments that are temperature-insensitive. TFF technology is designed to improve the solubility and absorption of poorly water-soluble drugs and is particularly suited to generate dry powder particles with properties targeted for inhalation delivery.

The first two countermeasures were TFFD formulated and tested for efficacy with in vitro neutralization assays; they include monoclonal antibodies (mAbs) against filovirus zaire ebolavirus (EBOV) and a recombinant vesicular stomatitis virus (rVSV) vaccine candidate against the alphavirus Venezuelan equine encephalitis virus.

The data showed that the activity of the mAbs and rVSV vaccine candidate were preserved after TFFD; formulation optimization and long-term stability testing are ongoing. The next steps will be in vivo testing in appropriate animal models, according to the company.

TFF, Augmenta Bioworks partner on COVID-19 mAbs
TFF Pharmaceuticals and Augmenta Bioworks have agreed to work together to develop COVID-19 monoclonal antibody (mAb) therapies.
Experic expands manufacturing capabilities with TFF Pharmaceuticals
TFF Pharmaceuticals has expanded its relationship with Experic, a contract manufacturing organization, to install a thin-film freezing processing line...
Union Therapeutics licenses COVID-19 tech from TFF
Union Therapeutics has completed an agreement with TFF Pharmaceuticals to obtain a worldwide exclusive license for the use of its thin film freezing technology...
Universal flu vaccine R&D collaboration established
Clinical-stage biopharmaceutical company TFF Pharmaceuticals has partnered with researchers at the University of Georgia and University of Texas to evaluate...

Copyright © 2021

BioProcess International (BPI) Conference
September 27-30
Boston, Massachusetts United States
Laboratory Products Association Annual Meeting
October 1-4
Scottsdale, Arizona United States
Cell & Gene Meeting on the Mesa
October 11-13
Carlsbad, California United States
IDWeek 2022
October 19-23
District of Columbia United States
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter